Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 350.5% in October

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 241,900 shares, a growth of 350.5% from the October 15th total of 53,700 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading volume of 268,900 shares, the days-to-cover ratio is presently 0.9 days.

Tiziana Life Sciences Trading Down 1.3 %

Shares of NASDAQ TLSA traded down $0.01 during mid-day trading on Tuesday, reaching $0.94. The company had a trading volume of 249,670 shares, compared to its average volume of 208,947. Tiziana Life Sciences has a twelve month low of $0.41 and a twelve month high of $1.74. The stock’s 50 day moving average is $0.94 and its 200-day moving average is $0.93.

Institutional Investors Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC boosted its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the quarter. Zhang Financial LLC owned about 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.